95 related articles for article (PubMed ID: 9324294)
21. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
22. Ex vivo cytokine activation of peripheral blood stem cells: a potential role for adoptive cellular immunotherapy.
Meehan KR; Wu A; Hassan R; Miao Y; Chawla J; Slack R; Gehan E; Herscowitz HB
J Hematother Stem Cell Res; 2001 Apr; 10(2):283-90. PubMed ID: 11359675
[TBL] [Abstract][Full Text] [Related]
23. Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure.
Maciejewski JP; Hibbs JR; Anderson S; Katevas P; Young NS
Exp Hematol; 1994 Oct; 22(11):1102-10. PubMed ID: 7925777
[TBL] [Abstract][Full Text] [Related]
24. WT1 gene expression lowered by IL-12 In vitro in peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes.
Pan L; Zhang XJ; Niu ZY; Suo XH; Zhang JY; Yang L; Liu XJ; Qiao SK; Dong ZR; Ohno R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):501-7. PubMed ID: 16800930
[TBL] [Abstract][Full Text] [Related]
25. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
Naume B; Gately M; Espevik T
J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
[TBL] [Abstract][Full Text] [Related]
26. Bone marrow and peripheral blood natural killer cell activity in lymphomas. Its response to IL-2.
Caldera LH; Leon-Ponte M; Acquatella G; Bianco NE; Blanca I
Clin Exp Immunol; 1992 Apr; 88(1):143-8. PubMed ID: 1373350
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-2 therapy for myelodysplastic syndrome: does it work?
Ogata K; Yokose N; Nomura T
Leuk Lymphoma; 1995 May; 17(5-6):411-5. PubMed ID: 7549831
[TBL] [Abstract][Full Text] [Related]
28. Long-term cultures of mouse bone marrow cells: a model for studying the generation of natural killer cells.
Ayroldi E; Cannarile L; D'Adamio F; Delfino D; Migliorati G; Riccardi C
Nat Immun; 1992; 11(6):317-27. PubMed ID: 1477494
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 matrix protein p17 enhances the proliferative activity of natural killer cells and increases their ability to secrete proinflammatory cytokines.
Vitale M; Caruso A; De Francesco MA; Rodella L; Bozzo L; Garrafa E; Grassi M; Gobbi G; Cacchioli A; Fiorentini S
Br J Haematol; 2003 Jan; 120(2):337-43. PubMed ID: 12542496
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: differential effects at different time points.
Verma UN; Mazumder A
Bone Marrow Transplant; 1995 Sep; 16(3):365-72. PubMed ID: 8535308
[TBL] [Abstract][Full Text] [Related]
31. Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin-2.
Lotzová E; Savary CA; Schachner JR; Huh JO; McCredie K
Am J Hematol; 1991 Jun; 37(2):88-99. PubMed ID: 2069169
[TBL] [Abstract][Full Text] [Related]
32. Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12.
Mehrotra PT; Donnelly RP; Wong S; Kanegane H; Geremew A; Mostowski HS; Furuke K; Siegel JP; Bloom ET
J Immunol; 1998 Mar; 160(6):2637-44. PubMed ID: 9510161
[TBL] [Abstract][Full Text] [Related]
33. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
[TBL] [Abstract][Full Text] [Related]
34. Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients.
Mirjačić Martinović K; Babović N; Džodić R; Jurišić V; Matković S; Konjević G
J Transl Med; 2015 Apr; 13():120. PubMed ID: 25889680
[TBL] [Abstract][Full Text] [Related]
35. Unique phenotype of human uterine NK cells and their regulation by endogenous TGF-beta.
Eriksson M; Meadows SK; Wira CR; Sentman CL
J Leukoc Biol; 2004 Sep; 76(3):667-75. PubMed ID: 15178706
[TBL] [Abstract][Full Text] [Related]
36. Novel aspects of in vitro IL-2 or IFN-α enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction.
Konjević G; Mirjačić Martinović K; Vuletić A; Radenković S
Biomed Pharmacother; 2010 Dec; 64(10):663-71. PubMed ID: 20800424
[TBL] [Abstract][Full Text] [Related]
37. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.
Carlsten M; Baumann BC; Simonsson M; Jädersten M; Forsblom AM; Hammarstedt C; Bryceson YT; Ljunggren HG; Hellström-Lindberg E; Malmberg KJ
Leukemia; 2010 Sep; 24(9):1607-16. PubMed ID: 20613786
[TBL] [Abstract][Full Text] [Related]
38. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes.
Kiladjian JJ; Bourgeois E; Lobe I; Braun T; Visentin G; Bourhis JH; Fenaux P; Chouaib S; Caignard A
Leukemia; 2006 Mar; 20(3):463-70. PubMed ID: 16408099
[TBL] [Abstract][Full Text] [Related]
39. Ex vivo expansion of T, NK and CD34+ cells from umbilical cord blood.
Wei YM; Cao Q; Zhou HY; Xia R; Lan JC; Meng FY; Bai H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1076-81. PubMed ID: 16403284
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.
Fuchshuber PR; Lotzová E; Pollock RE
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):51-9. PubMed ID: 1651770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
